Darodipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Darodipine
Accession Number
DB09234
Type
Small Molecule
Groups
Experimental
Description

Darodipine is a calcium channel blocker.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
N4AL7X96GL
CAS number
72803-02-2
Weight
Average: 371.393
Monoisotopic: 371.148120788
Chemical Formula
C19H21N3O5
InChI Key
QERUYFVNIOLCHV-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N3O5/c1-5-25-18(23)14-10(3)20-11(4)15(19(24)26-6-2)16(14)12-8-7-9-13-17(12)22-27-21-13/h7-9,16,20H,5-6H2,1-4H3
IUPAC Name
3,5-diethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OCC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Darodipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Darodipine.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Darodipine.Approved, Investigational
AmobarbitalThe metabolism of Darodipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Darodipine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Darodipine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Darodipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Darodipine.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Darodipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Darodipine is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Darodipine.Experimental
BarbexacloneThe metabolism of Darodipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Darodipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Darodipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Darodipine.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Darodipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Darodipine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Darodipine.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Darodipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Darodipine.Approved
Calcium AcetateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Darodipine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Darodipine.Experimental
CarbomycinThe metabolism of Darodipine can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Darodipine.Approved, Investigational
CaseinThe therapeutic efficacy of Darodipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Darodipine.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Darodipine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Darodipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Darodipine.Approved, Investigational
CimetidineThe serum concentration of Darodipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Darodipine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Darodipine.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Darodipine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Darodipine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Darodipine.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Darodipine.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Darodipine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Darodipine.Approved
EfavirenzThe serum concentration of Darodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Darodipine.Approved
ErythromycinThe metabolism of Darodipine can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Darodipine.Experimental
FluconazoleThe serum concentration of Darodipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Darodipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Darodipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Darodipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Darodipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Darodipine.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Darodipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Darodipine.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Darodipine.Approved, Investigational
HexobarbitalThe metabolism of Darodipine can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Darodipine.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Darodipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Darodipine.Approved, Investigational
JosamycinThe metabolism of Darodipine can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Darodipine.Approved, Investigational
KitasamycinThe metabolism of Darodipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Darodipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Darodipine.Experimental
MethohexitalThe metabolism of Darodipine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Darodipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Darodipine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Darodipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Darodipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Darodipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Darodipine.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Darodipine.Experimental
NafcillinThe metabolism of Darodipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Darodipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Darodipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Darodipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Darodipine.Investigational
NitroprussideDarodipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Darodipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Darodipine.Approved, Vet Approved
OleandomycinThe metabolism of Darodipine can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Darodipine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Darodipine.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Darodipine.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Darodipine.Approved
PentobarbitalThe metabolism of Darodipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Darodipine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Darodipine.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Darodipine.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Darodipine.Approved
PrimidoneThe metabolism of Darodipine can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Darodipine.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Darodipine.Experimental
RifabutinThe serum concentration of Darodipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Darodipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Darodipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Darodipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Darodipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Darodipine.Approved, Vet Approved
SecobarbitalThe metabolism of Darodipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Darodipine.Approved
SilodosinSilodosin may increase the hypotensive activities of Darodipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Darodipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Darodipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Darodipine.Approved, Investigational
SolithromycinThe metabolism of Darodipine can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Darodipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Darodipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Darodipine.Approved
TelithromycinThe metabolism of Darodipine can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Darodipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Darodipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Darodipine.Approved
ThiamylalThe metabolism of Darodipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Darodipine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Darodipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Darodipine.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Darodipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Darodipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Darodipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Darodipine.Approved, Investigational
TylosinThe metabolism of Darodipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Darodipine is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Darodipine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Darodipine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
51701
PubChem Substance
310265138
ChemSpider
46790
ChEMBL
CHEMBL2104154
Wikipedia
Darodipine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.258 mg/mLALOGPS
logP4.08ALOGPS
logP1.94ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)19.45ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.55 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.41 m3·mol-1ChemAxon
Polarizability37.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoxadiazoles. These are organic compounds containing a benzene fused to an oxadiazole ring (a five-membered ring with two carbon atoms, one nitrogen atom, and one oxygen atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxadiazoles
Sub Class
Not Available
Direct Parent
Benzoxadiazoles
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Dicarboxylic acids and derivatives / Benzenoids / Vinylogous amides / Heteroaromatic compounds / Furazans / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines
show 5 more
Substituents
Benzoxadiazole / Dihydropyridinecarboxylic acid derivative / Dihydropyridine / Dicarboxylic acid or derivatives / Benzenoid / Hydropyridine / Azole / Heteroaromatic compound / Furazan / Vinylogous amide
show 20 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:27 / Updated on December 01, 2017 16:14